HK Stock Market Move | Asymchem Laboratories (06821) increases over 10%, adjusted net profit attributable to shareholders increases by nearly 28% in the first quarter, and revenue from emerging businesses grows by 70% year-on-year.

Asymchem Laboratories (06821) rose more than 10%, up 10% to HK$115.5 at the time of publication, with a turnover of HK$172 million. On the news front, on the evening of April 27, Asymchem Laboratories released its first quarter 2026 performance, with operating income of approximately HK$1.802 billion, an increase of 16.91% year-on-year; net profit attributable to shareholders of the listed company was approximately HK$304 million, a decrease of 6.82% year-on-year. The company stated that the decrease in net profit was mainly due to a high exchange loss caused by the appreciation of the RMB, while there was an exchange gain in the same period last year. Adjusted net profit attributable to shareholders of the listed company was HK$423 million, an increase of 27.91% year-on-year. In terms of business segments, in the first quarter, the revenue of the small molecule CDMO business was HK$1.2 billion, an increase of 0.43% year-on-year, or 3.26% at constant exchange rates; revenue of emerging businesses was HK$598 million, an increase of 74.07% year-on-year, mainly driven by strong growth in the chemical and biological large molecule business segments. Huatai stated that the company expects a 19%-22% year-on-year growth in revenue for the full year 2026. Considering the company's leading technology and continuous development of emerging businesses, the company is optimistic about achieving rapid growth in the full year 2026.